Ann: Phosphagenics Pain Program Update , page-42

...looks like someone needs to do a bit of reaserch himself...

Maybe you.

Here's the skinny on insulin. The transdermal insulin product was and remains a "niche" product. There is no way it should be seen as a substitute for the jab, and for that reason is is wholly misleading to look at the entire market for insulin supplementation as the target for the insulin patch which has no application for acute requirements. Insulin-dependent diabetics will still need their kits with them.

The insulin patch is useful for maintaining basal insulin levels. This is important in Type 1 diabetes, less so in the far larger population of Type 2 diabetes sufferers, many of whom are not insulin dependent in any case.

Also keep in mind that diabetes treatment is very competitive and fast changing with new products to control blood sugar coming along at a regular pace, such as Bydureon, which has made it possible for many patients to wean off insulin altogether.

Then there is the cost of the trials. Insulin through completion of Phase 3 will cost in the order to ten times as much as any of the opiates.

So yes, oxycodone (more properly opiates) larger than insulin? Actually yes; from every practical standpoint, a very confident yes. Larger and far less risk and a lower cost of entry.

A no-brainer.